Sanius Health Celebrates World CML Day | Accelerating the Future of Empowered Patient Care

Every year on the 22nd of September, World Chronic Myeloid Leukaemia (CML) Day is a day for the haematology community to recognise the need to raise awareness, celebrate achievements, and recommit itself to supporting those with this condition. For our ecosystem, It is a time for us to reflect on the strides made by the global CML community and to renew our focus on what still needs to be accomplished.

In recent years, we've witnessed remarkable progress in the understanding and treatment of CML. The approval of Asciminib as a therapeutic option has offered patients the hope of improved outcomes in managing their condition. This innovative treatment, which targets the ABL myristoyl pocket (STAMP inhibitor), represents a significant leap forward in precision medicine for CML. Successes like these are not just a testament to scientific advancement but also to the increased utility of real-world evidence (RWE) to understand the longitudinal impacts of therapies on quality of life, treatment outcomes, and patient experiences.

RWE has played a crucial role in validating clinical trial results in diverse patient populations, like many of those in the Sanius Health community, providing insights into long-term safety profiles, and helping to identify subgroups of patients who may benefit most from specific treatments. Moreover, this approach has enabled the healthcare community to better understand the day-to-day challenges faced by CML patients, leading to more holistic care strategies that address not only the physical aspects of the disease but also the emotional and social dimensions.?

However, despite these significant strides, there is still much work to be done. While treatments like Asciminib offer new hope, not all patients respond equally, and some continue to face challenges with treatment resistance or intolerance. There remains a pressing need to further refine our understanding of CML patient experience, develop even more targeted therapies, and improve strategies for early detection and intervention. As stated by one of Sanius Health’s clinical partners Dr. Jane Apperley, Chair of the Department of Haematology at Imperial College London,? we must continue building technologies, capabilities and solutions that support this end:

“For the vast majority of patients, CML is now a chronic disease, completely compatible with a normal life. But critical in achieving this is remembering to take the drug every day. Sometimes people forget, sometimes they get side effects they want to avoid. Keeping a record of your health and discussing any problems with your health care providers is the best way to find a drug, a dose and a regime to help you optimise your outcome.”

The CML community must continue to advocate for equitable access to innovative therapies, specialised care, and support services. Furthermore, there is an ongoing need to enhance patient education, improve adherence to treatment regimens, and develop more personalised approaches to care that take into account individual patient preferences and quality of life considerations. By addressing these challenges and leveraging the power of collaborative research, data sharing, and patient engagement, we can work towards a future where CML is not just manageable, but potentially curable for all patients.

In addition, Mhairi Copland, Professor of Translational Haematology at the University of Glasgow, emphasised the importance of working as a community to refine how we approach personalised - and ultimately, better care for patients: "We must recognise that only by uniting the voices of clinicians, researchers, and patients can we truly innovate and co-develop solutions that meaningfully improve patient outcomes. Our collective wisdom, when harmonised, becomes the catalyst for transformative healthcare advancements."

As an ecosystem, we are deeply committed to continue supporting the CML community. Sanius Health’s MyCML+ is designed to empower patients by offering comprehensive tools to manage their health more effectively. Beyond tracking treatment and managing drug interactions, MyCML+ enables patients to monitor their health outcomes and enhance their overall well-being.

As we look to the future, World CML Day is also a time to think critically about how we can continue supporting those living with CML. We believe that accelerating research opportunities and deepening our understanding of each patient’s CML journey are crucial steps towards improving patient care. By collaborating with clinical and research partners, we are working with the community to better care pathways, and also provide patients with the tools they need to take an active role in their own health.

The CML community has made tremendous progress, but our journey is far from over. Together, we must continue to push the boundaries of what’s possible in research, treatment, and patient empowerment. As we commemorate World CML Day, we are celebrating our achievements while staying focused on the road ahead—ensuring that every person with CML has the opportunity to live a healthier, more empowered life.

To learn more about how Sanius Health is supporting CML patients on World CML Day and beyond, visit: www.saniushealth.com